Catalent (NYSE:CTLT) had its price objective boosted by research analysts at Jefferies Financial Group from $44.00 to $50.00 in a report released on Tuesday, The Fly reports. The firm presently has a “hold” rating on the stock. Jefferies Financial Group’s price objective indicates a potential upside of 16.96% from the stock’s current price. Jefferies Financial Group also issued estimates for Catalent’s Q4 2019 earnings at $0.63 EPS, FY2019 earnings at $1.71 EPS, Q1 2020 earnings at $0.21 EPS, Q2 2020 earnings at $0.46 EPS, Q3 2020 earnings at $0.45 EPS, Q4 2020 earnings at $0.73 EPS and FY2020 earnings at $1.85 EPS.
A number of other research analysts have also issued reports on CTLT. ValuEngine lowered Catalent from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Zacks Investment Research upgraded Catalent from a “sell” rating to a “hold” rating in a report on Tuesday, January 8th. TheStreet upgraded Catalent from a “c” rating to a “b-” rating in a report on Wednesday, February 6th. First Analysis reiterated an “outperform” rating and issued a $49.00 target price on shares of Catalent in a report on Tuesday, March 5th. Finally, UBS Group upgraded Catalent from a “neutral” rating to a “buy” rating and lifted their target price for the company from $43.00 to $54.00 in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $49.57.
Shares of NYSE CTLT opened at $42.75 on Tuesday. Catalent has a twelve month low of $29.23 and a twelve month high of $46.43. The company has a quick ratio of 1.63, a current ratio of 2.08 and a debt-to-equity ratio of 1.36. The firm has a market capitalization of $6.47 billion, a PE ratio of 26.89, a PEG ratio of 2.43 and a beta of 1.69.
In other Catalent news, insider Aristippos Gennadios sold 3,392 shares of Catalent stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $42.18, for a total transaction of $143,074.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Lance Miyamoto sold 43,619 shares of Catalent stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $42.49, for a total value of $1,853,371.31. The disclosure for this sale can be found here. Insiders have sold a total of 54,326 shares of company stock valued at $2,303,676 over the last ninety days. 1.40% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the company. Nordea Investment Management AB lifted its holdings in shares of Catalent by 36.0% in the 3rd quarter. Nordea Investment Management AB now owns 109,694 shares of the company’s stock valued at $4,997,000 after purchasing an additional 29,008 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Catalent by 29.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock valued at $363,316,000 after purchasing an additional 1,819,020 shares during the last quarter. First Bank & Trust lifted its holdings in shares of Catalent by 13.9% in the 4th quarter. First Bank & Trust now owns 4,600 shares of the company’s stock valued at $143,000 after purchasing an additional 563 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Catalent by 234.5% in the 3rd quarter. AQR Capital Management LLC now owns 82,106 shares of the company’s stock valued at $3,740,000 after purchasing an additional 57,562 shares during the last quarter. Finally, Blueshift Asset Management LLC purchased a new stake in shares of Catalent in the 4th quarter valued at about $815,000. 99.82% of the stock is owned by institutional investors and hedge funds.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Story: Blue-Chip Stocks
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.